Diagnosis and management of Clostridium difficile infection - PubMed (original) (raw)
Review
. 2013 Oct;11(10):1216-23; quiz e73.
doi: 10.1016/j.cgh.2013.03.016. Epub 2013 Mar 28.
Affiliations
- PMID: 23542332
- DOI: 10.1016/j.cgh.2013.03.016
Review
Diagnosis and management of Clostridium difficile infection
Herbert L Dupont. Clin Gastroenterol Hepatol. 2013 Oct.
Abstract
Clostridium difficile infection (CDI) is increasing in frequency and severity in and out of the hospital, with a high probability of recurrence after treatment. The recent literature on CDI was reviewed using PubMed to include recent publications dealing with diagnosis and therapy. Real-time polymerase chain reaction is a sensitive and useful diagnostic test for CDI but there are growing concerns of false-positive test results if the rate of CDI is low in the patient population providing samples and/or if the population being studied commonly includes people with C difficile colonization. Recommended therapy of CDI includes oral metronidazole for milder cases of CDI and oral vancomycin or fidaxomicin for more severe cases, each given for 10 days. Colectomy is being performed more frequently in patients with fulminant CDI. For treatment of first recurrences the drug used in the first bout can be used again and for second recurrences longer courses of vancomycin often are given in a tapered dose or intermittently to allow gut flora reconstitution, or other treatments including fidaxomicin may be used. Bacteriotherapy with fecal transplantation is playing an increasing role in therapy of recurrent cases. Metagenomic studies of patients with CDI during successful therapy are needed to determine how best to protect the flora from assaults from antibacterial drugs and to develop optimal therapeutic approaches. Immunotherapy and immunoprophylaxis offer opportunities to prevent CDI, to speed up recovery from CDI, and to eliminate recurrent infection. Humanized monoclonal antitoxin antibodies and active immunization with vaccines against C difficile or its toxins are both in development and appear to be of potential value.
Keywords: Antibiotic-associated Diarrhea; CDI; Clostridium difficile Infection; Clostridium difficile infection; Fidaxomicin; GDH; Metronidazole; Microbiome; NAP1; North American pulse-field type 1; Oral Vancomycin; PPV; RT-PCR; glutamate dehydrogenase; positive predictive value; real-time polymerase chain reaction.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
Similar articles
- Clostridium difficile infection in older adults: a review and update on its management.
Kee VR. Kee VR. Am J Geriatr Pharmacother. 2012 Feb;10(1):14-24. doi: 10.1016/j.amjopharm.2011.12.004. Epub 2012 Jan 20. Am J Geriatr Pharmacother. 2012. PMID: 22260856 Review. - Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS. Cocanour CS. Surg Infect (Larchmt). 2011 Jun;12(3):235-9. doi: 10.1089/sur.2010.080. Epub 2011 Jul 18. Surg Infect (Larchmt). 2011. PMID: 21767157 Review. - Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
Cornely OA. Cornely OA. Clin Microbiol Infect. 2012 Dec;18 Suppl 6:28-35. doi: 10.1111/1469-0691.12012. Clin Microbiol Infect. 2012. PMID: 23121552 Review. - Challenges and opportunities in the management of Clostridium difficile infection.
DuPont HL. DuPont HL. Expert Rev Gastroenterol Hepatol. 2014 Nov;8(8):863-74. doi: 10.1586/17474124.2014.939630. Epub 2014 Jul 11. Expert Rev Gastroenterol Hepatol. 2014. PMID: 25012255 Review. - Therapeutic approaches for Clostridium difficile infections.
Marsh JW, Curry SR. Marsh JW, et al. Curr Protoc Microbiol. 2013 Oct 2;30:9A.3.1-9A.3.9. doi: 10.1002/9780471729259.mc09a03s30. Curr Protoc Microbiol. 2013. PMID: 24510892
Cited by
- Fecal microbiota transplantation for Clostridium difficile infection in patients with ileal pouches.
Lan N, Ashburn J, Shen B. Lan N, et al. Gastroenterol Rep (Oxf). 2017 Aug;5(3):200-207. doi: 10.1093/gastro/gox018. Epub 2017 May 16. Gastroenterol Rep (Oxf). 2017. PMID: 28852524 Free PMC article. - Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015.
Carmo J, Marques S, Chapim I, Túlio MA, Rodrigues JP, Bispo M, Chagas C. Carmo J, et al. GE Port J Gastroenterol. 2015 Aug 31;22(6):259-267. doi: 10.1016/j.jpge.2015.07.006. eCollection 2015 Nov-Dec. GE Port J Gastroenterol. 2015. PMID: 28868417 Free PMC article. Review. - Direct cost of health care for individuals with community associated Clostridium difficile infections: A population-based cohort study.
Singh H, Nugent Z, Walkty A, Yu BN, Lix LM, Targownik LE, Bernstein CN, Witt J. Singh H, et al. PLoS One. 2019 Nov 8;14(11):e0224609. doi: 10.1371/journal.pone.0224609. eCollection 2019. PLoS One. 2019. PMID: 31703080 Free PMC article. - Determining the risk factors associated with the development of Clostridium difficile infection in patients with hematological diseases.
Lee-Tsai YL, Luna-Santiago R, Demichelis-Gómez R, Ponce-de-León A, Ochoa-Hein E, Tamez-Torres KM, Bourlon MT, Bourlon C. Lee-Tsai YL, et al. Blood Res. 2019 Jun;54(2):120-124. doi: 10.5045/br.2019.54.2.120. Epub 2019 Jun 25. Blood Res. 2019. PMID: 31309090 Free PMC article. - Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.
Koon HW, Ho S, Hing TC, Cheng M, Chen X, Ichikawa Y, Kelly CP, Pothoulakis C. Koon HW, et al. Antimicrob Agents Chemother. 2014 Aug;58(8):4642-50. doi: 10.1128/AAC.02783-14. Epub 2014 Jun 2. Antimicrob Agents Chemother. 2014. PMID: 24890583 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources